{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"115"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"116"}],"units":"Participants"}],"description":"An AE was defined as any noxious, pathologic, or unintended change in anatomical, physiologic, or metabolic function as indicated by physical signs, symptoms, or laboratory changes occurring in any phase of a clinical study, whether or not considered study drug related. This included an exacerbation of a pre-existing condition. TEAEs were defined as any new AEs that began or any pre-existing conditions that worsen in severity from the first dose of study drug through 30 days after the last dose or prior to the subsequent therapy, whichever occurs first.. A summary of all SAEs and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.","groups":[{"description":"Participants received IMGN632 via IV infusion on Day 1 of each 21-day cycle.","id":"OG000","title":"Schedule A: IMGN632 0.045 mg/kg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The safety population included all participants who received at least 1 dose of study drug. Here, 'Overall number of participants analyzed' = participants treated with IMGN632 at the RP2D.","reportingStatus":"POSTED","timeFrame":"Up to approximately 81 months","title":"Number of Participants With TEAEs in Participants Who Received IMGN632 As a Single Agent at the RP2D Level (0.045 mg/kg)","type":"SECONDARY","unitOfMeasure":"Participants"}